Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 1,926 Cr.
- Current Price ₹ 534
- High / Low ₹ 886 / 367
- Stock P/E
- Book Value ₹ 303
- Dividend Yield 0.00 %
- ROCE -8.65 %
- ROE -33.4 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 126 to 99.5 days.
- Company's working capital requirements have reduced from 198 days to 124 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.45% over past five years.
- Company has a low return on equity of -11.3% over last 3 years.
- Promoters have pledged 34.6% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,310 | |
462 | 1,173 | 1,065 | 1,232 | 1,187 | 1,309 | 1,384 | 1,139 | |
Operating Profit | 59 | 214 | 257 | 385 | 81 | 134 | -95 | 171 |
OPM % | 11% | 15% | 19% | 24% | 6% | 9% | -7% | 13% |
2 | 12 | 27 | 28 | 14 | 22 | -184 | -118 | |
Interest | 25 | 82 | 78 | 84 | 75 | 90 | 106 | 116 |
Depreciation | 34 | 83 | 94 | 108 | 112 | 111 | 103 | 100 |
Profit before tax | 2 | 61 | 112 | 221 | -92 | -45 | -488 | -164 |
Tax % | 0% | 3% | 0% | 0% | -36% | -50% | 16% | |
2 | 59 | 112 | 221 | -59 | -22 | -567 | -253 | |
EPS in Rs | 17.06 | 31.42 | 46.13 | -12.20 | -4.63 | -118.10 | -52.36 | |
Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | -7% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | -7% |
1 Year: | 5% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -11% |
Last Year: | -33% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
Reserves | 745 | 937 | 1,064 | 1,557 | 1,491 | 1,467 | 901 | 1,051 |
633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 840 | |
414 | 456 | 339 | 397 | 373 | 379 | 398 | 355 | |
Total Liabilities | 1,817 | 1,957 | 2,152 | 2,610 | 2,937 | 2,895 | 2,347 | 2,286 |
1,063 | 1,195 | 1,374 | 1,359 | 1,334 | 1,342 | 1,261 | 1,224 | |
CWIP | 70 | 39 | 40 | 88 | 239 | 238 | 256 | 272 |
Investments | 19 | 18 | 18 | 18 | 15 | 16 | 14 | 2 |
666 | 705 | 719 | 1,145 | 1,350 | 1,298 | 815 | 788 | |
Total Assets | 1,817 | 1,957 | 2,152 | 2,610 | 2,937 | 2,895 | 2,347 | 2,286 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
50 | 166 | 242 | 154 | -242 | 156 | 111 | |
-85 | -113 | -359 | -105 | -243 | -81 | -5 | |
67 | -23 | 97 | 92 | 334 | -113 | -107 | |
Net Cash Flow | 32 | 30 | -20 | 142 | -151 | -38 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 185 | 76 | 63 | 109 | 141 | 136 | 99 |
Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 |
Days Payable | 420 | 126 | 131 | 154 | 150 | 139 | 140 |
Cash Conversion Cycle | 17 | 62 | 102 | 104 | 312 | 256 | 123 |
Working Capital Days | 112 | 36 | 68 | 119 | 253 | 216 | 124 |
ROCE % | 10% | 12% | 15% | -1% | 2% | -9% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Apr - Solara Active Pharma Sciences Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2025
-
Notice On The First Call Money Of The Rights Equity Shares.
9 Apr - Despatch of First Call Money Notice to shareholders.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Apr - Solara Active Pharma Sciences Limited has informed about Copy of the Newspaper publications made by the Company on the Record date fixed for the purpose …
-
Board Meeting Outcome for Outcome Of The Rights Issue Committee Meeting_Solara Active Pharma Sciences Limited
2 Apr - Approval of first call money notice for rights issue.
-
Announcement under Regulation 30 (LODR)-Meeting Updates
2 Apr - Approval of first call money notice for rights issue.
Annual reports
Concalls
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPTREC
-
Jun 2024TranscriptPPTREC
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]